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Summary
Objective: To better understand transcription regulation of osteoarthritis (OA) by examining common promoter motifs in canine osteoarthritic
genes, to identify other genes containing these motifs and to assess the conservation of these motifs between canine, human, mouse and rat.
Design: Differentially expressed transcripts in canine OA were mapped to the human genome. We thus identiﬁed 20 orthologous human tran-
scripts representing 19 up-regulated genes and 62 orthologous transcripts representing 60 down-regulated genes. The 5 kbp upstream re-
gions of these transcripts were used to identify binding sites and build promoter models based on those sites. The human genome was
subsequently searched for other transcripts likely to be regulated by the same promoter models. Orthologous transcripts were then identiﬁed
in canine, rat and mouse for determination of potential cross-species conservation of binding sites comprising the promoter model.
Results: Four promoter models containing 5e6 transcripts and 5e8 common transcription factor binding sites were developed. They include
binding sites for AP-4, AP-2a and g, and E2F. Several hundred other human genes were found to contain these promoter motifs. Furthermore
these motifs were signiﬁcantly over represented in the orthologous genes in canine, rat and mouse genomes.
Conclusions: We have developed and applied a computational methodology to identify common promoter elements implicated in OA and
shared amongst four higher vertebrates. The transcription factors associated with these binding sites and other genes driven by these pro-
moter motifs have been implicated in OA, chondrocyte development and with other biological factors involved in the disease.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) affects 20% of the general canine popu-
lation and 12% of the human population aged 25e741,2. OA
is a chronic degenerative disease characterized by the
breakdown of articular cartilage. Inﬂammation is sometimes
present, but not always. The degeneration of cartilage is
a result of cartilage matrix dynamics being shifted in favor
of catabolism over anabolism.
Molecular research of OA has included the identiﬁcation
of multiple changes at the protein or transcript level simulta-
neously. Key targets identiﬁed include matrix metalloprotei-
nases (MMPs), speciﬁc tissue inhibitors of metalloproteinases
(TIMPs), proinﬂammatory cytokines, insulin-like growth
factors (IGFs) and other players known to be involved in
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mation. Groups of these are involved in common biological
pathways and are likely to be driven by common regulatory
mechanisms involving transcription factors and their associ-
ated DNA binding sites in gene regulatory regions. Thus the
elucidation of signiﬁcant motifs in these regulatory regions
would give us a greater understanding of the mechanisms
of disease etiology.
We had previously identiﬁed approximately 220 differen-
tially expressed osteoarthritic genes using a canine OA
microarray developed from differential display.3 We de-
scribe here the development of promoter models by using
cis-regulatory elements associated with the human ortho-
logs of these genes. In addition, the human genome was
searched for other genes likely to be driven by the same
promoter elements in an attempt to identify other genes
potentially involved in OA pathogenesis. The human genes
thus identiﬁed contain sets of cis-regulatory elements that
are also found in corresponding regions of the orthologous
genes in the canine, mouse and rat genomes, suggesting
the conservation of gene function in degenerative joint
disease.0
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PROMOTER MODEL DEVELOPMENT
The computational pipeline developed for the analysis is
depicted in Fig. 1. Approximately 220 differentially ex-
pressed canine OA transcripts were mapped to human tran-
scripts and the corresponding human transcripts were used
to identify common transcription factor binding sites 5 kb up-
stream of the transcription start sites4. Multiple transcripts
for a gene were used if the 50 ends of the (alternative) tran-
scripts were greater than 1500 bp apart. This ensured the
inclusion of representative sets of transcripts while avoiding
redundancy. Promoter model identiﬁcation was performed
separately for up and down-regulated genes. Twenty hu-
man transcripts derived from 19 genes that were up-regu-
lated and 62 transcripts derived from 60 genes that were
down-regulated were used. A graph theoretic approach for
transcription model discovery was used as described5.
Brieﬂy, given the set of upstream regions and the set of
potential binding sites in these regions, our approach is to
identify large subsets of genes sharing a large set of
common binding sites in their upstream regions. This can
be done using algorithms for a well-studied problem of
clique-enumeration from the computer science literature.
The binding site annotation was based on known transcrip-
tion factor binding speciﬁcities from TRANSFAC database6
as well as humanemouse conservation as described7.
Each of the four identiﬁed models included 5e6 transcripts
containing 5e8 common transcription factor binding sites in
their 5 kbp upstream regions (Tables I and II).
Fig. 1. The computational pipeline for transcriptional analysis of OA.
We employed a previously described method for whole genome
prediction of transcription factor binding sites7. Differentially
expressed genes in canine OA are mapped to human transcripts.
The corresponding 5 kb region upstream of the gene start for these
human orthologs is used for promoter modeling as described previ-
ously5. The promoter models consist of sets of transcription factors
which are then used to identify additional human genes which are
likely to be under similar coordinated regulation and thus putatively
involved in OA. In order to determine whether this set of putative,
model identiﬁed, gene set is likely to be co-coordinately regulated
they are used to identify orthologous genes in dog, mouse and
rat. The upstream 5 kb regions of these orthologous canine and
rodent genes are searched for the promoter model to evaluate
the conservation of promoter model across species.IDENTIFICATION OF OTHER GENES CONTAINING
THE PROMOTER MODELS
After the transcriptional models were developed, the
human genome was scanned for other transcripts likely to
be regulated by the same models, as evidenced by the pres-
ence of potential binding sites in their 5 kb upstream regions.
After the discovery of the initial set of such transcripts, an
additional ﬁltering step was employed. Only the transcripts
with an average cis-similarity (averaged over the cis-similar-
ities against the initial differentially expressed transcript) of at
least 2 standard deviations above the mean were retained.
Cis-similarity is a measure of commonality between the
cis-elements in the upstream region of two genes. The
mean and standard deviation of cis-similarity were based
on a large set of unrelated transcript pairs. The retained tran-
scripts for each model now represent the output.
DOG, MOUSE AND RAT ORTHOLOGS
For each of the four models, the output set of human tran-
scripts was used to identify the canine orthologs using
BLAST8. Orthologs were accepted when a sufﬁcient length
of match was obtained between the human transcript and
dog genomic sequence (minimum 70% sequence identity
for 80 nucleotides) and when the 50 end of the human tran-
script aligned well. In particular, orthologs were discarded
when more than 30 bp of the 50 end of the human transcript
was not aligned. The identiﬁcation of the mouse and rat
orthologs of human genes proceeded in a different manner
than for canine due to the presence of independently anno-
tated gene, transcript and protein set for those genomes
(www.ensembl.org). Mutually best protein alignments were
identiﬁed between the humanemouse and humanerat
sequence sets by using BLASTP and identifying all proteins
where greater than 50% of their length occurred in
alignment blocks of 25 amino acids at greater than 65%
sequence identity. We thus identiﬁed 14,326 humane
mouse and 13,294 humanerat orthologs. These protein or-
thologs could be trivially associated to transcripts to identify
the corresponding 5 kbp upstream regions for promoter
analysis.
CONSERVATION OF PROMOTER MODELS IN DOG, MOUSE
AND RAT
Five kilobase (or less when unavailable) upstream of the
putative canine (similarly for mouse and rat) transcripts
were searched for the transcriptional model (presence of
potential binding sites) in these regions. Redundancy
among the upstream regions was removed using the nonre-
dundant database (nrdb) program (http://blast.wustl.edu/
pub/nrdb/executables/). Unlike the search on human tran-
scripts for the initial model construction, the conservation
criterion of the transcription factor binding site hits was not
used. Also there is inherent redundancy among the binding
site proﬁles represented in the TRANSFAC database. For
instance many binding site proﬁles correspond to same
biological factor, e.g., Sp1 and many proﬁles corresponding
to different factors are still very similar. Such a redundancy
in the motifs representing a model would lead to wrong
estimation of the enrichment. We have developed an
approach to remove such redundant proﬁles. For example,
down-regulated model 2 has eight factors e M00008 (Sp1),
M00118 (cMyc/Max), M00189 (AP-2), M00243 (Egr-1),
M00244 (NGFI-C), M00255 (GC_Box), M00324 (Muscle_
initiator_sequence-20), and M00333 (ZF5). Four of these
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The human orthologs of differentially regulated canine transcripts in the discovered promoter models. X denotes transcripts associated with
each individual model
Gene symbol Description Up-regulated
model 1
Down-regulated
model 1
Down-regulated
model 2
Down-regulated
model 3
SMPD3 Sphingomyelin phosphodiesterase X
Q9BYE2_HUMAN Protease, serine, 11 (IGF-binding) X
CHAD Chondroadherin X
DGCR2 DiGeorge syndrome
critical region gene 2
X
SLC39A7 HLA class II region
gene KE4 aka solute
carrier family 39 (zinc transporter),
member 7
X
NFAT2 Nuclear factor
of activated T-cells 5
X X
SOX-9 SRY-box 9 X X
HELZ Helicase with
zinc ﬁnger domain
X
THBS1 Thrombospondin X X X
VAV1 VAV proto-oncogene related X X X
HK2 Hexokinase 2 X X X
ARID4A RBP1 X
ATXN1 Spinocerebellar ataxia 1 X
PCSK5 Proprotein convertase
subtilisin/kexin type 5
X Xproﬁles are very similar to each other, three of which were
removed, resulting in a set of ﬁve proﬁles in this model.
A promoter was considered ‘‘hit’’ by a model if every
transcription factor in the model had a binding site in the
promoter region. For each of the four models, the upstream
sequences (of orthologous genes) were searched for the
transcription factors comprising the corresponding model
using the pwm_scan program with a P-value threshold of
9.217. At this threshold we expect to see a hit once every5000 bp (on either strand) on average i.e., the chance of
a hit at any given position is 1/5000. Assuming positional
independence of hits with positional hit probability P ¼ 1/
5000 and upstream region length L, the probability of ob-
serving at least one hit in the region (on either strand) is
P ¼ 1 ð1 1=5000ÞL. If there are F proﬁles in the model,
assuming independence among these proﬁles, the proba-
bility of observing a hit for each of the F proﬁles is PF. If
there are N orthologous genes with an average upstreamTable II
Transcription factors associated with the up- and down-regulated promoter models as inferred by the presence of their cognate binding sites in
the promoters of transcripts in the model (Table I). X denotes transcription factors associated with each individual model. Note that each model
contains a distinct set of transcription factors and those comprising the up-regulated model are quite different from those of the three down-
regulated models
Transcription factor Up-regulated
model 1
Down-regulated
model 1
Down-regulated
model 2
Down-regulated
model 3
Activating enhancer
binding protein 4
X
GATA binding
protein 1
X
GATA binding
protein 2
X
Muscle initiator sequence-19 X
Muscle initiator sequence-20 X X X X
Testis speciﬁc
protein NYD-TSP1
X
SP1 X X X
GC box X X X
Zinc ﬁnger
protein 161 homolog
X X X
Activating enhancer
binding protein 2 alpha
X X
Activating enhancer
binding protein 2 gamma
X X X
E2F1 X X
cMyc/Max X X
EGR 1 X
EGR 4 X
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regions containing a hit for each of the F proﬁles as
E ¼ N PF. Let the actual number of upstream regions hit
by all F proﬁles be O, then the enrichment of the model in
the particular species (dog, mouse or rat) is O/E. Table III
shows the results of this enrichment analysis for dog,
mouse and rat. Columns 2e4 show N, O, E, and O/E. After
removing redundant positional weight matrices (PWMs) in
the models as described earlier, F ¼ 5 for up-regulated
model 1 and F ¼ 6, 5, and 6 for down-regulated models
1e3, respectively. L ¼ 3700 bps (on average, based on se-
quence availability) for dog, and 5000 bps for mouse and rat.
GENE ONTOLOGY AND BIOLOGICAL ASSOCIATION ANALYSIS
Signiﬁcant Gene Ontology biological processes repre-
sented by human genes containing the promoter models
were determined by calculating a P-value which indicated
which biological processes were over represented in the list
of selected genes9. Only those processes where P< 0.05
and greater than 2 nodes were represented in a branch
were retained (Table IV). Biological associations were deter-
mined for each set of human genes containing the promoter
models using the software program Pathway Assist (Strata-
gene, USA). Associations (regulation, transport, binding,
etc.) were assigned using natural language scans of Medline
abstracts and databases such as DIP and BIND. Down-
regulated promoter model 2 protein associations were devel-
oped by displaying only direct interactions (Fig. 2).
Results
PROMOTER MODELS
The discovered promoter models identiﬁed many tran-
scription factors known to be associated with osteoarthritic
genes but also included a few novel ones. One model
was detected for up-regulated transcripts (Table II). How-
ever, three models for down-regulated transcripts had the
same number of genes and transcription factors and hence
all three of them were considered. The up-regulated model
contains binding sites for transcription factors activating en-
hancer binding protein (AP) 4, GATA binding protein 1 and 2
(GATA-1 and -2), muscle initiator sequence-19 and -20,
and testis speciﬁc protein NYD-TSP1. AP-4, GATA-1 and -2
have previously been identiﬁed as being associated with
common gene targets in OA10,11. The down-regulated
models share multiple binding sites. These include SP1,
GC box, muscle initiator sequence-20, zinc ﬁnger protein
161 homolog and AP-2g. In addition, E2F1, cMyc/Max andAP-2a binding sites are present in two models. Early growth
response (EGR) 1 and 4 are only present in model 2. Like the
up-regulated model, these models involve transcription
factors previously associated with common gene targets in
OA. These include Sp1, E2F1, AP-2, and cMyc/Max12e15.
An interesting ﬁnding is the presence of muscle initiator
sequence-20 in the three down-regulated models and also
found in the up-regulated model. Little is known about this
transcription factor including its relevance to OA.
GENES CONTAINING THE PROMOTER MODELS
The presence of binding sites for transcription factors that
constitute an OA promoter model in the promoter region of
a candidate gene might suggest that the gene is also co-
ordinately regulated with genes involved in OA. We identi-
ﬁed novel candidate genes involved in OA by scanning
the human genome for the promoter models. We thus iden-
tiﬁed 723 transcripts containing the up-regulated model.
Corresponding numbers for the three down-regulated
models were 535, 518 and 799 with 337 transcripts com-
mon to all down-regulated models. Of these, 320, 298,
284 and 404 nonredundant locus links were identiﬁed for
up-regulated model 1 and down-regulated models 1e3, re-
spectively. These sets of transcripts were used to determine
if any Gene Ontology biological process was signiﬁcantly
represented. As shown in Table IV, several areas of tran-
scription regulation and development are signiﬁcant for all
transcript sets. Pathway analysis of these sets of transcripts
(down-regulated model 2 shown as a representative exam-
ple) shows a concentration of targets associated with tumor
necrosis factor (TNF), insulin and transforming growth fac-
tor-b (TGF-b) (Fig. 2). Known associations (regulation,
transport, binding, etc.) are represented by links between
nodes (gene, transcript or protein product). Seventy of the
284 transcripts identiﬁed using down-regulated promoter
model 2 (25%) have an association with TGF-b, TNF and/
or insulin. Similar results were obtained for other models
(data not shown).
CONSERVATION OF PROMOTER MODELS IN DOG, MOUSE
AND RAT
Next we investigated whether the binding sites in human
promoters are conserved in the corresponding canine and
rodent orthologs. We found a higher than expected conser-
vation of promoter models which further strengthens the
validity of these promoter models and indicates evolutionary
conservation of the processes involved in OA. The canine
orthologs of the human genes identiﬁed by the promoterTable III
Conservation of promoter models in upstream regions of dog, mouse and rat. Human genes possessing the promoter models in the 5 kbp
upstream were used to identify orthologs in dog, mouse and rat. The number of identified orthologs is shown in column 2. The upstream region
of the orthologs was searched for the binding sites constituting the promoter model. The number of orthologs containing the model is shown in
column 3. Column 4 shows the expected number of orthologs containing the model as described in Materials and methods and column 5
shows the enrichment as a ratio of observed/expected. Note that all models shown occur significantly in the orthologs of the three species
examined suggesting an evolutionary conservation of the gene set involved in OA
Model Number of genes
(dog/mouse/rat)
Observed number of
genes containing all PWM
hits (dog/mouse/rat)
Expected number of
genes containing all PWM
hits (dog/mouse/rat)
Ratio of observed/expected
for dog/mouse/rat
Up-regulated model 1 165/97/95 102/68/64 9/10/10 11.3/6.8/6.4
Down-regulated model 1 138/84/80 63/52/48 2/5/5 31.5/10.4/9.6
Down-regulated model 2 133/82/75 52/42/39 6/8/8 8.7/5.2/4.8
Down-regulated model 3 181/107/101 43/42/41 4/7/6 10.8/6.0/6.8
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Gene Ontology biological process table. The P-value indicates whether a given biological process was over represented in the list of selected
genes or has been selected by chance. The significant (P< 0.05) biological processes represented by human transcripts containing the cis-
binding elements of each model are indicated. Missing values represent those with P> 0.05
Gene Ontology
biological process
Promoter model P-value
Up Down 1 Down 2 Down 3
Regulation of transcription, DNA-dependent 0.0010 4.3Ee06 3.5Ee07 1.8Ee06
Regulation of transcription 5.5Ee07 6.8Ee06 5.7Ee07 3.1Ee06
Transcription, DNA-dependent 0.0017 8.0Ee06 6.8Ee07 3.8Ee06
Transcription 0.0011 1.6Ee05 1.4Ee06 8.6Ee06
Morphogenesis 0.0157 1.1Ee04 2.6Ee04 0.0052
Nucleobase, nucleoside,
nucleotide and nucleic
acid metabolism
0.0236 6.0Ee04 2.6Ee04 4.2Ee04
Organogenesis 0.0499 7.5Ee04 0.0018 0.0167
Development 0.0112 0.0014 0.0023 0.0279
Central nervous
system development
0.0129
Potassium ion transport 0.0426 0.0201 0.0108
Regulation of transcription
from Pol II promoter
0.0371 0.0237
Metabolism 0.0177
Metal ion transport 0.0433
Neurogenesis 0.0472models were identiﬁed using the CanFam 1.0 assembly
(ftp://ftp/ncbi.nih.gov/genomes/Canis_familiaris/). The fol-
lowing number of canine genes were identiﬁed: up-regu-
lated model 1 e 165; down-regulated model 1 e 138;down-regulated model 2 e 133; and down-regulated model
3 e 181. The corresponding numbers of mouse genes iden-
tiﬁed were 97, 84, 82 and 107 and rat genes were 95, 80, 75
and 101, respectively. We assessed whether the promoterFig. 2. Human transcripts containing the cis-binding elements of down-regulated model 2 associate with TNF, insulin and TGFb1. Nodes rep-
resent transcripts identiﬁed and links represent known interactions or modulations from neighboring nodes. Links: regulation, gray square;
protein modiﬁcation, yellow circle; promoter binding, green circle; molecular transport, green open square; molecular synthesis, blue open
square; expression, blue square; direct regulation, green square; and binding, purple circle.
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genes are enriched in the cis-elements corresponding to
the transcription factors in the corresponding model. As
shown in Table III, all of the models are highly enriched in
the promoter regions of the transcripts in dog, mouse and
rat orthologous to human genes obtained by the direct
model searching. For instance, in dog among 165 tran-
scripts, we expect to see only nine transcripts to contain
all of the ﬁve transcription factor binding sites in their upstream
regions, however, we observe 102 such transcripts e
11-fold enrichment. The results for dog, mouse and rat indi-
cate a potentially similar transcriptional control in all three
species. In addition, the enrichment is higher for dog vs hu-
man than for mouse or rat vs human. This is consistent with
a previous analysis of orthologous repeats between human,
mouse and dog16. Human and dog genome sequences
were shown to be more similar to each other than human
and mouse.
Discussion
TRANSCRIPTS USED FOR REGULATORY MODEL
DEVELOPMENT
The transcripts used for regulatory model development
(Table I) were chosen based on their differential expres-
sion in canine OA and the inclusion of a set of common
binding sites in their upstream regions. These transcripts
represent the basis for which the promoter models were
developed. Their known function in the disease did not
play a role in the model development. Their function, how-
ever, may give us a broad understanding of the role these
models play in the disease. The transcripts in the up-
regulated model include sphingomyelin phosphodiester-
ase, serine protease 11 (IGF-binding) and chondroadherin,
among others. Sphingomyelin phosphodiesterase is better
known for its involvement in NiemannePick disease but
the product from its catalysis of sphingomyelin, ceramide,
plays a role as a mediator in apoptosis and matrix degra-
dation in cartilage17. Serine protease 11 (IGF-binding) is
proposed to cleave IGF-binding proteins, thus regulating
the availability of IGFs18. IGFs have anabolic effects on
chondrocytes. This includes the ability to stimulate the
production of proteoglycan19. In osteoarthritic cartilage,
serine protease 11’s RNA and protein expression is
increased20. The cartilage matrix protein chondroadherin
may mediate cell-to-matrix binding. It binds collagen type
II and the integrin a2b121. It may also play a role in the
assembly of collagen due to its territorial matrix expres-
sion. Taken together, the regulation of these genes may
represent a coordinated matrix development, differentiation
or reorganization pathway.
Transcripts in the down-regulated models include SRY
(sex determining region Y)-box 9 (SOX-9), thrombospondin
1, proprotein convertase subtilisin/kexin type 5 and retino-
blastoma binding protein 1 (RBP1), among others. SOX-9
is a transcription factor whose role in cartilage development
has been well characterized. SOX-9 plays a major role in
chondrogenesis, partly by its ability to induce the expres-
sion of chondrocyte-speciﬁc genes, such as collagen
IIA22,23. The expression of SOX-9 is increased in early
chondrogenesis but there is a decrease in its expression
in metabolically inactive chondrocytes, which associates
with a decrease in the proteoglycan matrix and the chondro-
cyte phenotype24,25. In addition, SOX-9 is down-regulated
by the E2F1 transcription factor26. E2F transcription factors
stimulate the expression of genes involved in the cell cycleand possibly tumor suppression. They can also inhibit the
expression of genes by forming a complex with the retino-
blastoma protein (pRb), which leads to cell cycle arrest
(see also RBP1 and E2F1 discussion). The down-regulation
of SOX-9 by E2F1 is consistent with our model, since it
contains an E2F1 binding site (Table II). Thrombospondin
1 is an extracellular glycoprotein involved in cellematrix
interactions and the activation of TGF-b27. In severe OA
there is a decrease in thrombospondin associated with a
decrease in cartilage matrix28. The human thrombospondin
gene contains both an AP-2 binding site and a GC box,
which is consistent with our ﬁndings (Table II)29. Proprotein
convertase subtilisin/kexin type 5 is a protease that regu-
lates the activity of membrane type-1 MMPs (MT1-
MMP)30. MT1-MMPs are involved in a latent-form to
active-form metalloproteinase cascade leading to the acti-
vation of MMP-13 and -931. These MMPs are well known
for their cartilage destruction in OA.
RBP1 is a pRb pocket binding protein. It binds pRB/E2F
(along with histone deacetylase) in the repression of E2F
binding site-related genes32. This results in the inhibition
of growth promoting protein expression. Although the
down-regulation of RBP1 (Table I) and the presence of an
E2F1 site in the other down-regulation models (Table II)
may tie these models together, the decrease in expression
of these genes could be contradictory. Theoretically, the de-
crease in expression of RBP1 should lead to an increase in
expression of E2F binding site-containing genes. This
would only apply to genes whose E2F-required expression
is inhibited by pRb. SOX-9, as an example, contains an
E2F1-binding site and is down-regulated in our model. Its
expression, however, is down-regulated by E2F1 in U2OS
cells, but not differentially regulated by pRb26,33. Future
studies will need to be performed to elucidate the interaction
of RBP1 and E2F family members in OA.
The transcripts in the down-regulated promoter models
are involved in both cartilage matrix degradation and chon-
drocyte differentiation. While most of these are part of well-
characterized biological pathways, these pathways may
interact, or may be part of a larger, expanded biological re-
sponse affecting both matrix turnover and differentiation.
These simultaneous biological responses are consistent
with the observation that osteoarthritic chondrocytes return
to a chondroprogenitor phenotype. Since the genes
involved with these responses contain similar cis-regulatory
elements, their transcriptional regulation would be a mecha-
nism by which these responses could be coordinated.
REGULATORY MODEL TRANSCRIPTION FACTORS
Many of the transcription factors associated with the pro-
moter models identiﬁed here have been independently
identiﬁed in the regulatory regions of known osteoarthritic
genes (Table II). As was the case with the differentially ex-
pressed transcripts discussed above, the function of the
transcription factors and the genes for which they bind did
not play a role in model development. However, what is
known about their function lends further support for the
models representing a coordinately regulated mechanism
of matrix development and chondrocyte differentiation.
The transcription factor AP-4, identiﬁed in up-regulated
model 1, has previously been shown to play a role, along
with AP-1, in the interleukin-1 dependent expression of
TGF-b10. The promoter of the IGF binding protein-2, which
binds both IGF-1 and -2, also contains an AP-4 binding
site34. In addition, the orphan G-protein coupled receptor,
CMKLR1, involved in cartilage development, contains
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and the IGFs are potent anabolic factors while the
CMKLR1’s role beyond its implication in development has
not been well deﬁned. These anabolic factors share many
of the up-regulated model’s cis-binding elements. Even
though there are few previously known examples of osteo-
arthritic genes containing these cis-binding elements, the
function of these genes supports the anabolic side of this
model’s importance in matrix development, differentiation
or reorganization.
The cis-binding elements in the down-regulated models
are common to many genes involved in OA. As is the
case with the transcripts used to develop the models,
many of these are involved in chondrocyte differentiation.
Binding sites for two AP-2 transcription factors were de-
tected in the down-regulated models. AP-2a was detected
in down-regulated models 1 and 3, and AP-2g was detected
in all the three models. AP-2 transcription factors bind their
target DNA elements as a homodimer or as heterodimers
with other AP-2 family members. AP-2a has been impli-
cated as a negative regulator of chondrocyte differentia-
tion35. In chondrocytes, its expression decreases during
differentiation while its overexpression leads to a decrease
in type II and X collagen, as well as aggrecan. Aggrecan
contains both AP-2 and Sp1 sites. Both AP-2 and Sp1 bind-
ing to the aggrecan promoter is regulated by TGF-b and p38
MAP kinase in chondrogenic cells14. In addition, AP-2 reg-
ulates the chondrogenic gene, CD-RAP, which also con-
tains an Sp1 site, in addition to the AP-2 site in its
promoter36. CD-RAP’s expression is also regulated by
SOX-9. SOX-9 is one of the transcripts used to develop
down-regulated models 1 and 3. The presence of the AP-
2 and Sp1 binding sites, along with the differentiation affects
of their associated genes, supports the involvement of the
down-regulated models in chondrocyte differentiation.
Binding sites for the transcription factor Sp1 are present
in all three down-regulated models. Binding sites for Sp1
are fairly common and, as would be expected, many osteo-
arthritic genes containing an Sp1 site have been identiﬁed.
These include MMP-9, aggrecan and cartilage-derived reti-
noic acid-sensitive protein (CD-RAP)12,37,38. In addition,
Sp1 activity is increased in chondrocytes stimulated with
hyaluronan hexasaccharides39.
Further support of the down-regulated models represent-
ing a mechanism of coordinate regulation of differentiation
is the presence of E2F1, EGR-1 and cMyc/Max sites.
E2F1, as discussed earlier, stimulates the expression of
genes involved in the cell cycle and can inhibit the expres-
sion of genes by forming a complex with the pRb. The
E2F1 binding sites are present in both down-regulated
models 1 and 3, which were both developed with the
SOX-9 transcript (Tables I and II). The overexpression of
E2F1 not only down-regulates SOX-9 but also inhibits
chondrocyte differentiation13,26. EGR-1 is known for its in-
volvement in cartilage formation40. It is also down-regulated
in OA41.
cMyc/Max ties together many of the players discussed
thus far via its association with proteins of the anabolic pro-
tein TGF-b’s signal transduction cascade. The TGF-b signal
transduction pathway involves SMAD proteins. cMyc can
bind Sp1-SMAD complexes, inhibiting TGF-b induced tran-
scriptional activation of p15(Ink4B)15. p15(Ink4B) is a cyclin-
dependent kinase 4 (Cdk4) inhibitor. Cdk4 modulates the
association of the pRb with E2F transcription factors42. In
addition, thrombospondin, which is one of the transcripts
used in developing the down-regulated models, can
activate TGF-b27. This series of coordination betweencMyc/Max, TGF-b, thrombospondin and Cdk4e can be par-
tially explained by transcriptional regulation due to the pres-
ence of the cis-binding elements in the down-regulated
models. However, further work will be needed to sort out
the speciﬁc roles they play in chondrocyte differentiation.
GENE ONTOLOGY AND BIOLOGICAL ASSOCIATIONS
As shown in Table IV, human transcripts containing these
promoter models are over represented in multiple areas of
transcriptional regulation and development. This is indica-
tive of the importance and complexity of transcription in
the coordinated regulation of biological pathways, diseases
and development, all of which are tied together. The asso-
ciation of transcripts containing these promoter models with
development further supports their involvement in this area
of OA. This includes chondrocyte or matrix development,
differentiation and reorganization.
TNF, TGF-b, insulin, and their associated family mem-
bers are key players in OA as well as chondrocyte differen-
tiation and matrix reorganization. The involvement of the
models developed here with these key players is supported
by the magnitude of associations of transcripts driven by
these models and these three key players (Fig. 2). It is clear
from this broad view, that the models developed here in-
volve these players. This may not be direct regulation
(i.e., cis-binding), but may be down-stream events through
signal transduction cascades or other yet to be character-
ized biological pathways.
We have sought out to identify common gene regulatory
cis-elements associated with subsets of differentially ex-
pressed osteoarthritic transcripts. Four models have been
developed and are conserved in human, dog, mouse and
rat. The conservation gives further validity of the models,
since spurious matches would be less likely to be con-
served in the different species. Additionally, conservation
may also indicate a similarity in disease mechanisms
among the different species, further establishing their use
as model organisms. Taking into account the transcripts
used, the transcription factors associated with the cis-
binding elements and other transcripts driven by these
models, they may represent a coordinated regulation mech-
anism of chondrocyte differentiation or extracellular matrix
reorganization. The subtle differences between the three
down-regulated models may provide an efﬁcient means
for transcriptional regulation under varying conditions,
which still remains to be explored.
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